LoginSignup
Karuna Therapeu logo

Karuna Therapeu

Stock
Stock
ISIN: US48576A1007
Ticker: KRTX
US48576A1007
KRTX

Price

Price

Frequently asked questions

What is Karuna Therapeu's market capitalization?

The market capitalization of Karuna Therapeu is $12.58B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Karuna Therapeu?

Karuna Therapeu's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$11.73. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Karuna Therapeu's stock?

Currently, 17 analysts cover Karuna Therapeu's stock, with a consensus target price of $322.67. Analyst ratings provide insights into the stock's expected performance.

What is Karuna Therapeu's revenue over the trailing twelve months?

Over the trailing twelve months, Karuna Therapeu reported a revenue of $654.00K.

What is the EBITDA for Karuna Therapeu?

Karuna Therapeu's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$493.08M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Karuna Therapeu?

Karuna Therapeu has a free cash flow of -$388.74M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Karuna Therapeu's stock?

The 5-year beta for Karuna Therapeu is 1.15. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Karuna Therapeu have, and what sector and industry does it belong to?

Karuna Therapeu employs approximately 339 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Karuna Therapeu's shares?

The free float of Karuna Therapeu is 35.32M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $12.58B

5Y beta

 1.15

EPS (TTM)

 -$11.73

Free Float

 35.32M

Revenue (TTM)

 $654.00K

EBITDA (TTM)

 -$493.08M

Free Cashflow (TTM)

 -$388.74M

Pricing

52W span
$184.99$333.16

Analyst Ratings

The price target is $322.67 and the stock is covered by 17 analysts.

Buy

1

Hold

15

Sell

1

Information

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline built on the therapeutic potential of its lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. It is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, and for the treatment of psychosis in Alzheimer's disease. Its pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, and pre-clinical muscarinic, TRPC4/5 and target-agnostic compounds for the treatment of psychiatric and neurological conditions.

339

Biotechnology & Drugs

Health Care

Identifier

ISIN

US48576A1007

Primary Ticker

KRTX
Join the conversation
Sign upLogin